Clinical Trial Update: A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of AGN-190584 in both eyes twice daily for presbyopia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Presbyopia

Drugs mentioned

• AGN-190584

Snippet

Sponsor: Allergan | Conditions: Presbyopia | Phase 3 | Status: COMPLETED | Results posted: 2023-03-21